Experimental Therapeutics

实验治疗学

基本信息

批准号：
9122702
负责人：
Israel DAVID GOLDMAN
金额：
$ 25.28万
依托单位：
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至 2018-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9122702
关键词：
AIDS Malignancy Consortium Albert Einstein Cancer Center Antibodies Antibody Affinity Antineoplastic Agents Apoptotic Area Bioinformatics Biological Biological Products Breast Cancer Center Cancer Center Support Grant Cancer Therapy Evaluation Program Catalytic Domain Chemicals Clinic Clinical Clinical Investigator Clinical Oncology Clinical Services Clinical Treatment Clinical Trials Computational Biology Crystallography Dermatitis Development Disease Drug Design Eastern Cooperative Oncology Group Elements Enzymes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Funding Goals Grant Gynecologic Oncology Group Head and Neck Cancer Hematologic Neoplasms Home environment Immune Immune response Immunotherapeutic agent Instruction K-Series Research Career Programs Leadership Link Lung Malignant Neoplasms Malignant neoplasm of cervix uteri Malignant neoplasm of pancreas Mass Spectrum Analysis Medical Medical center Melanins Microtubule stabilizing agent Modification Monoclonal Antibodies Neuroendocrine Tumors New York Organized by Structure Protein Paper Pathway interactions Patient Recruitments Patients Pediatric Hematology Peer Review Pharmaceutical Preparations Phase I Clinical Trials Phase II Clinical Trials Physicians Play Polysaccharides Positioning Attribute Preclinical Drug Development Prevention Production Property Proteins Proteomics Shared Resource Publications Radiation Radiation Therapy Oncology Group Radioactive Radioisotopes Recruitment Activity Regimen Research Research Activity Research Personnel Rhenium Role Services Site Surface Surgical Oncologist Synapses Synthesis Chemistry System Therapeutic Translational trial aptamer base cancer care cancer cell cancer therapy chemical synthesis clinical efficacy college cytotoxic design drug development improved inhibitor/antagonist innovation melanoma member multidisciplinary neoplastic cell neuro-oncology novel oncology phase II trial programs screening structural biology tumor working group

项目摘要

PROJECT SUMMARY (See instructions): Experimental Therapeutics is the programmatic home for basic and clinical investigators involved in a broad spectrum of studies in cancer therapeutics. The goals of the program are: (1) to develop novel agents for the treatment of cancer based upon targets identified in this and other programs, (2) to improve the activities of established classes of drugs by structural modification and/or enhanced understanding of their pharmacological properties, (3) to develop more effective clinical therapeutic regimens within the context of disease-focused working groups. Preclinical drug development continues in the areas of transition-state inhibitors, novel microtubule-stabilizing agents, and a diverse spectrum of immunotherapeutics. Two transition-state inhibitors are now in clinical trials, one advanced. A third is moving forward to the clinic. A monoclonal antibody (moab) to melanin linked to 188-rhenium completed Phase I clinical trials for the treatment of advanced melanoma. Other moab-radionuclides are being developed targeting cervical and pancreatic cancers. An agent for the prevention of the dermatitis due to EGFR inhibitors recently entered a Phase II clinical trial. The spectrum of agents studied has broadened to encompassing aptamers, high-affinity antibodies, agents to block apoptotic pathways or targeted to surface glycans. Research in biologicals is focused on co-inhibitory elements within the immune synapse with the objective of developing agents that modulate tolerance, research activities supported by the expanding capabilities in protein production, synthetic chemistry, x-ray crystallography, NMR, and mass spectroscopy with bioinformatics and systems and computational biology support. Disease-focused working groups encompassing basic and clinical investigators have been expanded in breast, gynecological, lung, and head/neck cancers and in the hematological malignancies. Neuro-oncology and neuroendocrine tumors groups were recently formed. Recruitment of clinical and translational researchers has been enhanced by a recently funded Paul Calabresi Career Development Award for Clinical Oncology Scholars. Access to patients for clinical trials has been enhanced at the affiliated Montefiore Medical Center by the creation of the multidisciplinary Montefiore-Einstein Center for Cancer Care and the recruitment of a cadre of clinician investigators. AECC members play important roles in ECOG-ATRIN, GOG, COG, and the AIDS Malignancy Consortium. There are currently 54 members from 23 departments, supported by 10 NCI grants ($2.6M Direct) and 21 other peer-reviewed cancer-relevant grants ($10.2M Direct). Since the last CCSG review there have been 537 cancer-relevant research papers by members of this program of which 29% represent intraprogrammatic, and 27% represent interprogrammatic publications.

项目摘要（请参阅说明）：实验治疗是参与癌症治疗研究广泛研究的基础和临床研究人员的程序化所在地。该计划的目标是：（1）根据该计划中确定的靶标开发新的药物来治疗癌症，（2）通过结构修饰和/或增强对药理特性的了解，以改善已建立类别的药物的活动，（3）在疾病中疾病工作组的背景下开发更有效的临床治疗方案。在过渡态抑制剂，新型的微管稳定剂和各种免疫治疗药物的领域，临床前药物的发育持续。现在有两个过渡态抑制剂正在临床试验中，一个是晚期的。三分之一正在前进到诊所。与188- rhenium有关的黑色素的单克隆抗体（MOAB）完成了I期临床试验，以治疗晚期黑色素瘤。针对宫颈和胰腺癌的其他摩赤线核素正在开发。由于EGFR抑制剂而导致的预防皮炎的药物最近进入了II期临床试验。所研究的药物的光谱已扩大到包含适体，高亲和力抗体，阻断凋亡途径或靶向表面聚糖的代理。生物学研究的研究集中在免疫突触中的共抑制元素上，目的是开发可调节耐受性的剂，由蛋白质生产，合成化学，X射线晶体学，NMR和质量光谱质量的扩展能力所支持的研究活动，并具有生物信息和系统和计算生物学支持。包括疾病的工作组包括基本和临床研究者的乳房，妇科，肺和头部/颈部癌症以及血液学恶性肿瘤的扩展。最近形成了神经肿瘤学和神经内分泌肿瘤组。最近资助的Paul Calabresi职业发展奖临床肿瘤学者奖增强了临床和转化研究人员的招聘。通过创建多学科蒙特菲奥雷 - 因斯坦癌症护理中心并招募了临床研究人员的临床研究中心，蒙特菲奥尔医学中心附属的临床试验患者的访问已得到增强。 AECC成员在Ecog-Atrin，GOG，COG和AIDS恶性财团中扮演重要角色。目前有54个部门的成员来自23个部门，由10个NCI赠款（直接260万美元）和其他21个由同行评审的癌症与癌症的补助金（直接1020万美元）的支持。自从上次CCSG审查以来，该计划的成员已经发表了537个与癌症相关的研究论文，其中29％代表截面图，而27％代表了解释性的出版物。